Dear all; I am just wondering whether any regulatory (FDA, MHRA etc. ) guidance available on the starting dose of molecular targeted therapy (MTT) agents such as tyrosine kinase inhibitors in cancer patients. I would appreciate your thoughts on this topic.
Best regards, VPokiri >
